Skip to main content
. 2017 Dec;122(4):172–181. doi: 10.1016/j.ymgme.2017.10.004

Table 1.

OXPHOS spectrophotometric analyses.

Proband Tissue Complex I/CS Complex II/CS Complex II + III/CS Complex III/CS Complex IV/CS Citrate synthase
Proband 1 Skeletal muscle 67 [− 1.69] 149 [− 0.14] 128 [− 0.78] 260 [− 1.71] 337 [− 3.10] 347
Controls (n = 30) 170 ± 47 197 ± 40 200 ± 46 598 ± 204 1008 ± 287 174 ± 70
Proband 1 Cultured skin fibroblasts ND 116 [− 1.68] 168 [− 0.75] 495 [− 0.29] 352 [− 3.80] 94
Controls (n = 30) ND 189 ± 45 233 ± 71 586 ± 165 847 ± 169 82 ± 15
Proband 2 Skeletal muscle 168 [− 0.42] 386 [0.23] 330 [0.05] 88 [0.44] 21 [1.23] 183
Controls (n = 22) 178 ± 52 357 ± 131 276 ± 108 70 ± 49 11 ± 6 257 ± 69
Proband 2 Cultured skin fibroblasts 131 [− 2.04] 682 [0.54] 412 [1.51] 59 [1.13] 8 [− 1.27] 346
Controls (n = 32) 229 ± 75 595 ± 175 248 ± 85 39 ± 21 12 ± 5 407 ± 112

Data are expressed as the OXPHOS activity over citrate synthase activity. Between brackets is the Z-score based on the logarithm of OXPHOS activity divided by the logarithm of citrate synthase activity. Control sample ratios are given as mean ± SD. Z-scores lower than − 1.96 are significantly different (P < 0.05) from the control samples and are considered to be deficient activities. Deficient activities are shown in bold. ND: not determined. Citrate synthase activity expressed as nanomoles of substrate per minute per milligram of protein.